Darío Fernández Do Porto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Darío Fernández Do Porto has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Federico Serral
7 shared publications- Ezequiel Jorge Sosa
Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, UBA, Buenos Aires, Argentina
6 shared publications - Adrian Gustavo Turjanski
IQUIBICEN-CONICET, Ciudad Universitaria, Pabellón 2
5 shared publications - Marcelo Adrian Martí
University of Buenos Aires
5 shared publications Ezequiel J. Sosa
Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
4 shared publicationsGustavo Schottlender
Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CONICET, Universidad de Buenos Aires, Buenos Aires, Argentina
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Integrated genomic and functional characterization of a BI/NAP1/027 Clostridioides difficile strain reveals traits associated with persistence and virulence
Objectives: Hypervirulent BI/NAP1/027 strains of Clostridioides difficile have been associated with increased incidence, severity, and recurrence of C. difficile infection (CDI). This study aimed to perform a genomic and functional characterization of a BI/NAP1/027 strain (CDC20121308) to validate its use in C. difficile pathogenesis models.Methods: Whole-genome sequencing and comparative genomic analyses were performed to identify genetic determinants associated with virulence and antimicrobial resistance. Phenotypic assays assessed antibiotic susceptibility, motility, and biofilm formation. The pathogenic potential of CDC20121308 was evaluated through its interaction with enterocytes cell line and immune innate cells, as well as disease development in a murine infection model.Results: Whole-genome sequencing identified 3,717 coding sequences and 45 tRNAs, with approximately 26% of coding sequences assigned to RAST subsystems. Genome analysis revealed determinants associated with resistance to toxic compounds and antibiotics, including genes linked to vancomycin and tetracycline resistance, which was confirmed phenotypically. CDC20121308 also displayed a motile phenotype, formed biofilms, and carried a genomic region encoding components of a type IV secretion system. The strain induced marked cytotoxicity in Caco-2 monolayers, promoted severe intestinal pathology, and triggered pro-inflammatory responses in human innate immune cells.Conclusions: CDC20121308 retains the genomic and phenotypic traits associated with hypervirulent BI/NAP1/027 lineages, including antimicrobial resistance, motility, biofilm formation, and marked pathogenic potential. These findings support its use as a relevant experimental model for studying CDI pathogenesis and host-pathogen interactions.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntegrated genomic and functional characterization of a BI/NAP1/027 Clostridioides difficile strain reveals traits associated with persistence and virulence
Objectives: Hypervirulent BI/NAP1/027 strains of Clostridioides difficile have been associated with increased incidence, severity, and recurrence of C. difficile infection (CDI). This study aimed to perform a genomic and functional characterization of a BI/NAP1/027 strain (CDC20121308) to validate its use in C. difficile pathogenesis models.Methods: Whole-genome sequencing and comparative genomic analyses were performed to identify genetic determinants associated with virulence and antimicrobial resistance. Phenotypic assays assessed antibiotic susceptibility, motility, and biofilm formation. The pathogenic potential of CDC20121308 was evaluated through its interaction with enterocytes cell line and immune innate cells, as well as disease development in a murine infection model.Results: Whole-genome sequencing identified 3,717 coding sequences and 45 tRNAs, with approximately 26% of coding sequences assigned to RAST subsystems. Genome analysis revealed determinants associated with resistance to toxic compounds and antibiotics, including genes linked to vancomycin and tetracycline resistance, which was confirmed phenotypically. CDC20121308 also displayed a motile phenotype, formed biofilms, and carried a genomic region encoding components of a type IV secretion system. The strain induced marked cytotoxicity in Caco-2 monolayers, promoted severe intestinal pathology, and triggered pro-inflammatory responses in human innate immune cells.Conclusions: CDC20121308 retains the genomic and phenotypic traits associated with hypervirulent BI/NAP1/027 lineages, including antimicrobial resistance, motility, biofilm formation, and marked pathogenic potential. These findings support its use as a relevant experimental model for studying CDI pathogenesis and host-pathogen interactions.
- Open Access
Linking Genomic Virulence and Antimicrobial Resistance Determinants to Host-Interaction Phenotypes in the Emerging Bovine Mastitis Pathogen Enterococcus lactis
Enterococcus lactis is increasingly recognized as an emerging mastitis pathogen, yet the functional basis of its virulence and associated health risks remain poorly defined. This study presents an integrated genomic and phenotypic characterization of E. lactis strain EL-A150 isolated from bovine subclinical mastitis. Whole-genome sequencing revealed a 2.49 Mb circular chromosome encoding multiple genes associated with adhesion (acm, bepA, fms, sagA), biofilm formation (empB, empC) and antimicrobial resistance, including determinants related to aminoglycosides and macrolides. Phenotypic assays demonstrated rapid growth, strong biofilm-forming capacity and high adhesion to bovine mammary epithelial cells, while internalization remained low and intracellular persistence was transient. Comparative genomic analyses confirmed the taxonomic placement of the strain within the E. lactis clade (ANI up to 99.5% against reference genomes) and revealed a limited resistome composed of chromosomally encoded genes, with no detectable plasmids or major mobile genetic elements. Collectively, these findings demonstrate that E. lactis EL-A150 possesses a coordinated set of traits conducive to intramammary colonization, supporting its classification as an opportunistic pathogen. The convergence of virulence potential and clinically relevant antimicrobial resistance within a single isolate underscores a One Health concern and highlights the need for surveillance frameworks that integrate functional validation with genomic risk assessment.
Open AccessLinking Genomic Virulence and Antimicrobial Resistance Determinants to Host-Interaction Phenotypes in the Emerging Bovine Mastitis Pathogen Enterococcus lactis
Enterococcus lactis is increasingly recognized as an emerging mastitis pathogen, yet the functional basis of its virulence and associated health risks remain poorly defined. This study presents an integrated genomic and phenotypic characterization of E. lactis strain EL-A150 isolated from bovine subclinical mastitis. Whole-genome sequencing revealed a 2.49 Mb circular chromosome encoding multiple genes associated with adhesion (acm, bepA, fms, sagA), biofilm formation (empB, empC) and antimicrobial resistance, including determinants related to aminoglycosides and macrolides. Phenotypic assays demonstrated rapid growth, strong biofilm-forming capacity and high adhesion to bovine mammary epithelial cells, while internalization remained low and intracellular persistence was transient. Comparative genomic analyses confirmed the taxonomic placement of the strain within the E. lactis clade (ANI up to 99.5% against reference genomes) and revealed a limited resistome composed of chromosomally encoded genes, with no detectable plasmids or major mobile genetic elements. Collectively, these findings demonstrate that E. lactis EL-A150 possesses a coordinated set of traits conducive to intramammary colonization, supporting its classification as an opportunistic pathogen. The convergence of virulence potential and clinically relevant antimicrobial resistance within a single isolate underscores a One Health concern and highlights the need for surveillance frameworks that integrate functional validation with genomic risk assessment.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 5, 1695353
Beyond Tanimoto: a learned bioactivity similarity index enhances ligand discovery
Structural similarity metrics such as the Tanimoto coefficient (TC) miss many functionally related compounds—indeed, 60% of similarly bioactive ligand pairs in the ChEMBL database show TC < 0.30, revealing a major blind spot that constrains ligand-based discovery. Our motivation is to overcome this blind spot and enable the recovery of structurally different yet functionally equivalent chemotypes that structure-based similarity fails to detect. Here, we introduce the bioactivity similarity index (BSI), a machine learning model that estimates the probability that two molecules bind the same or related protein receptors. Trained under leave-one-protein-out (LOPO) across Pfam-defined protein groups on dissimilar pairs, BSI not only outperforms TC but also surpasses modern molecular embedding baselines (ChemBERTa and contrastive language-molecule pre-training (CLAMP), using cosine similarity) across protein families. We further develop a cross-family model (BSI-Large) that, while slightly below group-specific models, generalizes better and can be fine-tuned with less data, consistently improving over models trained from scratch. In retrospective validation on new ChEMBL v35 data, BSI achieves strong early-retrieval performance (top 2% enrichment factor, EF 2% ), with group-specific models delivering the best enrichment, and BSI-Large remaining competitive. In a realistic virtual screening-like scenario against the target gene ADRA2B, the mean rank of the next active, given a known active, improves from 45.2 (TC) to 3.9 (BSI), with 54.9 for ChemBERTa and 28.6 for CLAMP. Altogether, BSI complements, rather than replaces, structure-based similarity and embedding-based comparisons, extending hit finding to remote chemotypes that are structurally dissimilar yet functionally equivalent. The code is available at https://github.com/gschottlender/bioactivity-similarity-index .
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 5, 1695353
Open AccessBeyond Tanimoto: a learned bioactivity similarity index enhances ligand discovery
Structural similarity metrics such as the Tanimoto coefficient (TC) miss many functionally related compounds—indeed, 60% of similarly bioactive ligand pairs in the ChEMBL database show TC < 0.30, revealing a major blind spot that constrains ligand-based discovery. Our motivation is to overcome this blind spot and enable the recovery of structurally different yet functionally equivalent chemotypes that structure-based similarity fails to detect. Here, we introduce the bioactivity similarity index (BSI), a machine learning model that estimates the probability that two molecules bind the same or related protein receptors. Trained under leave-one-protein-out (LOPO) across Pfam-defined protein groups on dissimilar pairs, BSI not only outperforms TC but also surpasses modern molecular embedding baselines (ChemBERTa and contrastive language-molecule pre-training (CLAMP), using cosine similarity) across protein families. We further develop a cross-family model (BSI-Large) that, while slightly below group-specific models, generalizes better and can be fine-tuned with less data, consistently improving over models trained from scratch. In retrospective validation on new ChEMBL v35 data, BSI achieves strong early-retrieval performance (top 2% enrichment factor, EF 2% ), with group-specific models delivering the best enrichment, and BSI-Large remaining competitive. In a realistic virtual screening-like scenario against the target gene ADRA2B, the mean rank of the next active, given a known active, improves from 45.2 (TC) to 3.9 (BSI), with 54.9 for ChemBERTa and 28.6 for CLAMP. Altogether, BSI complements, rather than replaces, structure-based similarity and embedding-based comparisons, extending hit finding to remote chemotypes that are structurally dissimilar yet functionally equivalent. The code is available at https://github.com/gschottlender/bioactivity-similarity-index .
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1602
Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006–2015)
Tuberculosis (TB), caused by the intracellular bacterium Mycobacterium tuberculosis complex (Mtbc), remains a significant global health challenge, with Mtbc once again being the leading infectious killer worldwide. Despite over a century of research, the disease continues to pose a major threat, with an estimated one-fourth of the global population latently infected. According to the World Health Organization (WHO), approximately 1.3 million deaths were attributed to TB in 2024 alone. The emergence of multidrug-resistant (MDR) strains, resistant to isoniazid and rifampicin, and extensively drug-resistant (XDR) strains, resistant to rifampicin (and may also be resistant to isoniazid), to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug (bedaquiline or linezolid), further complicates the situation, posing significant challenges for healthcare systems. While the WHO definition of XDR-TB has recently been updated, in this study we applied the classification in effect during the 2006–2015 period, when the isolates were collected and characterized. In Argentina, TB burden is moderate compared to other countries, with approximately 10,500 new cases and 1,000 deaths reported annually. While standard therapy is generally effective, XDR Mtb infections require prolonged and costly treatment and are often associated with a guarded prognosis. In this work, we applied whole-genome sequencing analysis to characterise XDR-TB strains circulating in Argentina between 2006 and 2015. Genotypic variants of each isolate were compared against resistance-associated variant databases and subjected to local and global phylogenetic analyses. The analysis revealed no common origins for the most frequently observed resistance mutations. Notable variants associated with resistance to first-line drugs included katG Ser315Thr and fabG1 -15C < T for isoniazid, rpoB Ser450Leu and Asp435Val for rifampin, embB Gly406Ala, and Met306Ile for ethambutol, as well as multiple variants in the pncA gene linked to pyrazinamide resistance. This study provides valuable insights into the molecular mechanisms of antibiotic resistance in M. tuberculosis, specifically focusing on XDR strains circulating in Argentina. The findings highlight the genetic diversity and complexity of resistance-associated variants, emphasizing the need for continued research and surveillance efforts to address this pressing global health threat. Not applicable.
- 17 November 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1602
Open AccessGenomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006–2015)
Tuberculosis (TB), caused by the intracellular bacterium Mycobacterium tuberculosis complex (Mtbc), remains a significant global health challenge, with Mtbc once again being the leading infectious killer worldwide. Despite over a century of research, the disease continues to pose a major threat, with an estimated one-fourth of the global population latently infected. According to the World Health Organization (WHO), approximately 1.3 million deaths were attributed to TB in 2024 alone. The emergence of multidrug-resistant (MDR) strains, resistant to isoniazid and rifampicin, and extensively drug-resistant (XDR) strains, resistant to rifampicin (and may also be resistant to isoniazid), to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug (bedaquiline or linezolid), further complicates the situation, posing significant challenges for healthcare systems. While the WHO definition of XDR-TB has recently been updated, in this study we applied the classification in effect during the 2006–2015 period, when the isolates were collected and characterized. In Argentina, TB burden is moderate compared to other countries, with approximately 10,500 new cases and 1,000 deaths reported annually. While standard therapy is generally effective, XDR Mtb infections require prolonged and costly treatment and are often associated with a guarded prognosis. In this work, we applied whole-genome sequencing analysis to characterise XDR-TB strains circulating in Argentina between 2006 and 2015. Genotypic variants of each isolate were compared against resistance-associated variant databases and subjected to local and global phylogenetic analyses. The analysis revealed no common origins for the most frequently observed resistance mutations. Notable variants associated with resistance to first-line drugs included katG Ser315Thr and fabG1 -15C < T for isoniazid, rpoB Ser450Leu and Asp435Val for rifampin, embB Gly406Ala, and Met306Ile for ethambutol, as well as multiple variants in the pncA gene linked to pyrazinamide resistance. This study provides valuable insights into the molecular mechanisms of antibiotic resistance in M. tuberculosis, specifically focusing on XDR strains circulating in Argentina. The findings highlight the genetic diversity and complexity of resistance-associated variants, emphasizing the need for continued research and surveillance efforts to address this pressing global health threat. Not applicable.
- Open Access
- 16 April 2024
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 25, 100538
High-throughput prioritization of target proteins for development of new antileishmanial compounds
- 16 April 2024
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 25, 100538
Open AccessHigh-throughput prioritization of target proteins for development of new antileishmanial compounds
- Open Access
- 7 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1343029
Bacterial cytochrome P450s: a bioinformatics odyssey of substrate discovery
Bacterial P450 cytochromes (BacCYPs) are versatile heme-containing proteins responsible for oxidation reactions on a wide range of substrates, contributing to the production of valuable natural products with limitless biotechnological potential. While the sequencing of microbial genomes has provided a wealth of BacCYP sequences, functional characterization lags behind, hindering our understanding of their roles. This study employs a comprehensive approach to predict BacCYP substrate specificity, bridging the gap between sequence and function. We employed an integrated approach combining sequence and functional data analysis, genomic context exploration, 3D structural modeling with molecular docking, and phylogenetic clustering. The research begins with an in-depth analysis of BacCYP sequence diversity and structural characteristics, revealing conserved motifs and recurrent residues in the active site. Phylogenetic analysis identifies distinct groups within the BacCYP family based on sequence similarity. However, our study reveals that sequence alone does not consistently predict substrate specificity, necessitating additional perspectives. The study delves into the genetic context of BacCYPs, utilizing neighboring gene information to infer potential substrates, a method proven very effective in many cases. Molecular docking is employed to assess BacCYP-substrate interactions, confirming potential substrates and providing insights into selectivity. Finally, a comprehensive strategy is proposed for predicting BacCYP substrates, involving all the evaluated approaches. The effectiveness of this strategy is demonstrated with two case studies, highlighting its potential for substrate discovery.
- 7 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1343029
Open AccessBacterial cytochrome P450s: a bioinformatics odyssey of substrate discovery
Bacterial P450 cytochromes (BacCYPs) are versatile heme-containing proteins responsible for oxidation reactions on a wide range of substrates, contributing to the production of valuable natural products with limitless biotechnological potential. While the sequencing of microbial genomes has provided a wealth of BacCYP sequences, functional characterization lags behind, hindering our understanding of their roles. This study employs a comprehensive approach to predict BacCYP substrate specificity, bridging the gap between sequence and function. We employed an integrated approach combining sequence and functional data analysis, genomic context exploration, 3D structural modeling with molecular docking, and phylogenetic clustering. The research begins with an in-depth analysis of BacCYP sequence diversity and structural characteristics, revealing conserved motifs and recurrent residues in the active site. Phylogenetic analysis identifies distinct groups within the BacCYP family based on sequence similarity. However, our study reveals that sequence alone does not consistently predict substrate specificity, necessitating additional perspectives. The study delves into the genetic context of BacCYPs, utilizing neighboring gene information to infer potential substrates, a method proven very effective in many cases. Molecular docking is employed to assess BacCYP-substrate interactions, confirming potential substrates and providing insights into selectivity. Finally, a comprehensive strategy is proposed for predicting BacCYP substrates, involving all the evaluated approaches. The effectiveness of this strategy is demonstrated with two case studies, highlighting its potential for substrate discovery.
- Open Access
- 6 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Omics data integration facilitates target selection for new antiparasitic drugs against TriTryp infections
Introduction:Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp., commonly referred to as TriTryps, are a group of protozoan parasites that cause important human diseases affecting millions of people belonging to the most vulnerable populations worldwide. Current treatments have limited efficiencies and can cause serious side effects, so there is an urgent need to develop new control strategies. Presently, the identification and prioritization of appropriate targets can be aided by integrative genomic and computational approaches.Methods: In this work, we conducted a genome-wide multidimensional data integration strategy to prioritize drug targets. We included genomic, transcriptomic, metabolic, and protein structural data sources, to delineate candidate proteins with relevant features for target selection in drug development.Results and Discussion: Our final ranked list includes proteins shared by TriTryps and covers a range of biological functions including essential proteins for parasite survival or growth, oxidative stress-related enzymes, virulence factors, and proteins that are exclusive to these parasites. Our strategy found previously described candidates, which validates our approach as well as new proteins that can be attractive targets to consider during the initial steps of drug discovery.
- 6 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Open AccessOmics data integration facilitates target selection for new antiparasitic drugs against TriTryp infections
Introduction:Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp., commonly referred to as TriTryps, are a group of protozoan parasites that cause important human diseases affecting millions of people belonging to the most vulnerable populations worldwide. Current treatments have limited efficiencies and can cause serious side effects, so there is an urgent need to develop new control strategies. Presently, the identification and prioritization of appropriate targets can be aided by integrative genomic and computational approaches.Methods: In this work, we conducted a genome-wide multidimensional data integration strategy to prioritize drug targets. We included genomic, transcriptomic, metabolic, and protein structural data sources, to delineate candidate proteins with relevant features for target selection in drug development.Results and Discussion: Our final ranked list includes proteins shared by TriTryps and covers a range of biological functions including essential proteins for parasite survival or growth, oxidative stress-related enzymes, virulence factors, and proteins that are exclusive to these parasites. Our strategy found previously described candidates, which validates our approach as well as new proteins that can be attractive targets to consider during the initial steps of drug discovery.
- Open Access
- 20 October 2022
- Published by Frontiers Media SA in Frontiers in Drug Discovery
- Vol. 2
From drugs to targets: Reverse engineering the virtual screening process on a proteomic scale
Phenotypic screening is a powerful technique that allowed the discovery of antimicrobials to fight infectious diseases considered deadly less than a century ago. In high throughput phenotypic screening assays, thousands of compounds are tested for their capacity to inhibit microbial growth in-vitro. After an active compound is found, identifying the molecular target is the next step. Knowing the specific target is key for understanding its mechanism of action, and essential for future drug development. Moreover, this knowledge allows drug developers to design new generations of drugs with increased efficacy and reduced side effects. However, target identification for a known active compound is usually a very difficult task. In the present work, we present a powerful reverse virtual screening strategy, that can help researchers working in the drug discovery field, to predict a set of putative targets for a compound known to exhibit antimicrobial effects. The strategy combines chemical similarity methods, with target prioritization based on essentiality data, and molecular-docking. These steps can be tailored according to the researchers’ needs and pathogen’s available information. Our results show that using only the chemical similarity approach, this method is capable of retrieving potential targets for half of tested compounds. The results show that even for a low chemical similarity threshold whenever domains are retrieved, the correct domain is among those retrieved in more than 80% of the queries. Prioritizing targets by an essentiality criteria allows us to further reduce, up to 3–4 times, the number of putative targets. Lastly, docking is able to identify the correct domain ranked in the top two in about two thirds of cases. Bias docking improves predictive capacity only slightly in this scenario. We expect to integrate the presented strategy in the context of Target Pathogen database to make it available for the wide community of researchers working in antimicrobials discovery.
- 20 October 2022
- Published by Frontiers Media SA in Frontiers in Drug Discovery
- Vol. 2
Open AccessFrom drugs to targets: Reverse engineering the virtual screening process on a proteomic scale
Phenotypic screening is a powerful technique that allowed the discovery of antimicrobials to fight infectious diseases considered deadly less than a century ago. In high throughput phenotypic screening assays, thousands of compounds are tested for their capacity to inhibit microbial growth in-vitro. After an active compound is found, identifying the molecular target is the next step. Knowing the specific target is key for understanding its mechanism of action, and essential for future drug development. Moreover, this knowledge allows drug developers to design new generations of drugs with increased efficacy and reduced side effects. However, target identification for a known active compound is usually a very difficult task. In the present work, we present a powerful reverse virtual screening strategy, that can help researchers working in the drug discovery field, to predict a set of putative targets for a compound known to exhibit antimicrobial effects. The strategy combines chemical similarity methods, with target prioritization based on essentiality data, and molecular-docking. These steps can be tailored according to the researchers’ needs and pathogen’s available information. Our results show that using only the chemical similarity approach, this method is capable of retrieving potential targets for half of tested compounds. The results show that even for a low chemical similarity threshold whenever domains are retrieved, the correct domain is among those retrieved in more than 80% of the queries. Prioritizing targets by an essentiality criteria allows us to further reduce, up to 3–4 times, the number of putative targets. Lastly, docking is able to identify the correct domain ranked in the top two in about two thirds of cases. Bias docking improves predictive capacity only slightly in this scenario. We expect to integrate the presented strategy in the context of Target Pathogen database to make it available for the wide community of researchers working in antimicrobials discovery.
- Open Access
- 23 September 2022
- Published by Frontiers Media SA in Frontiers in Drug Discovery
- Vol. 2
Integrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes
Listeriamonocytogenes (Lm) is a Gram-positive bacillus responsible for listeriosis in humans. Listeriosis has become a major foodborne illness in recent years. This illness is mainly associated with the consumption of contaminated food and ready-to-eat products. Recently, Lm has developed resistances to a broad range of antimicrobials, including those used as the first choice of therapy. Moreover, multidrug-resistant strains have been detected in clinical isolates and settings associated with food processing. This scenario punctuates the need for novel antimicrobials against Lm. On the other hand, increasingly available omics data for diverse pathogens has created new opportunities for rational drug discovery. Identification of an appropriate molecular target is currently accepted as a critical step of this process. In this work, we generated multiple layers of omics data related to Lm, aiming to prioritize proteins that could serve as attractive targets for antimicrobials against L. monocytogenes. We generated genomic, transcriptomic, metabolic, and protein structural information, and this data compendium was integrated onto a freely available web server (Target Pathogen). Thirty targets with desirable features from a drug development point of view were shortlisted. This set of target proteins participates in key metabolic processes such as fatty acid, pentose, rhamnose, and amino acids metabolism. Collectively, our results point towards novel targets for the control of Lm and related bacteria. We invite researchers working in the field of drug discovery to follow up experimentally on our revealed targets.
- 23 September 2022
- Published by Frontiers Media SA in Frontiers in Drug Discovery
- Vol. 2
Open AccessIntegrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes
Listeriamonocytogenes (Lm) is a Gram-positive bacillus responsible for listeriosis in humans. Listeriosis has become a major foodborne illness in recent years. This illness is mainly associated with the consumption of contaminated food and ready-to-eat products. Recently, Lm has developed resistances to a broad range of antimicrobials, including those used as the first choice of therapy. Moreover, multidrug-resistant strains have been detected in clinical isolates and settings associated with food processing. This scenario punctuates the need for novel antimicrobials against Lm. On the other hand, increasingly available omics data for diverse pathogens has created new opportunities for rational drug discovery. Identification of an appropriate molecular target is currently accepted as a critical step of this process. In this work, we generated multiple layers of omics data related to Lm, aiming to prioritize proteins that could serve as attractive targets for antimicrobials against L. monocytogenes. We generated genomic, transcriptomic, metabolic, and protein structural information, and this data compendium was integrated onto a freely available web server (Target Pathogen). Thirty targets with desirable features from a drug development point of view were shortlisted. This set of target proteins participates in key metabolic processes such as fatty acid, pentose, rhamnose, and amino acids metabolism. Collectively, our results point towards novel targets for the control of Lm and related bacteria. We invite researchers working in the field of drug discovery to follow up experimentally on our revealed targets.
- 17 May 2022
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 38 (7) , 1-17
Genome mining of Burkholderia ambifaria strain T16, a rhizobacterium able to produce antimicrobial compounds and degrade the mycotoxin fusaric acid
Burkholderia ambifaria T16 is a bacterium isolated from the rhizosphere of barley plants that showed a remarkable antifungal activity. This strain was also able to degrade fusaric acid (5-Butylpyridine-2-carboxylic acid) and detoxify this mycotoxin in inoculated barley seedlings. Genes and enzymes responsible for fusaric acid degradation have an important biotechnological potential in the control of fungal diseases caused by fusaric acid producers, or in the biodegradation/bio catalysis processes of pyridine derivatives. In this study, the complete genome of B. ambifaria T16 was sequenced and analyzed to identify genes involved in survival and competition in the rhizosphere, plant growth promotion, fungal growth inhibition, and degradation of aromatic compounds. The genomic analysis revealed the presence of several operons for the biosynthesis of antimicrobial compounds, such as pyrrolnitrin, ornibactin, occidiofungin and the membrane-associated AFC-BC11. These compounds were also detected in bacterial culture supernatants by mass spectrometry analysis. In addition, this strain has multiple genes contributing to its plant growth-promoting profile, including those for acetoin, 2,3-butanediol and indole-3-acetic acid production, siderophores biosynthesis, and solubilisation of organic and inorganic phosphate. A pan-genomic analysis demonstrated that the genome of strain T16 possesses large gene clusters that are absent in the genomes of B. ambifaria reference strains. According to predictions, most of these clusters would be involved in aromatic compounds degradation. One genomic region, encoding flavin-dependent monooxygenases of unknown function, is proposed as a candidate responsible for fusaric acid degradation.
- 17 May 2022
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 38 (7) , 1-17
Genome mining of Burkholderia ambifaria strain T16, a rhizobacterium able to produce antimicrobial compounds and degrade the mycotoxin fusaric acid
Burkholderia ambifaria T16 is a bacterium isolated from the rhizosphere of barley plants that showed a remarkable antifungal activity. This strain was also able to degrade fusaric acid (5-Butylpyridine-2-carboxylic acid) and detoxify this mycotoxin in inoculated barley seedlings. Genes and enzymes responsible for fusaric acid degradation have an important biotechnological potential in the control of fungal diseases caused by fusaric acid producers, or in the biodegradation/bio catalysis processes of pyridine derivatives. In this study, the complete genome of B. ambifaria T16 was sequenced and analyzed to identify genes involved in survival and competition in the rhizosphere, plant growth promotion, fungal growth inhibition, and degradation of aromatic compounds. The genomic analysis revealed the presence of several operons for the biosynthesis of antimicrobial compounds, such as pyrrolnitrin, ornibactin, occidiofungin and the membrane-associated AFC-BC11. These compounds were also detected in bacterial culture supernatants by mass spectrometry analysis. In addition, this strain has multiple genes contributing to its plant growth-promoting profile, including those for acetoin, 2,3-butanediol and indole-3-acetic acid production, siderophores biosynthesis, and solubilisation of organic and inorganic phosphate. A pan-genomic analysis demonstrated that the genome of strain T16 possesses large gene clusters that are absent in the genomes of B. ambifaria reference strains. According to predictions, most of these clusters would be involved in aromatic compounds degradation. One genomic region, encoding flavin-dependent monooxygenases of unknown function, is proposed as a candidate responsible for fusaric acid degradation.